|
SERP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62492241884138E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.05546732149287E-13 |
| Normal-vs-Stage2 |
3.47339999995366E-06 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.70552461042917E-12 |
| Stage1-vs-Stage2 |
9.962400E-01 |
| Stage1-vs-Stage3 |
4.421500E-03 |
| Stage1-vs-Stage4 |
1.723760E-02 |
| Stage2-vs-Stage3 |
1.633970E-01 |
| Stage2-vs-Stage4 |
1.170400E-01 |
| Stage3-vs-Stage4 |
6.502600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.96062999999747E-05 |
| Normal-vs-Asian |
1.41500144934525E-11 |
| Caucasian-vs-AfricanAmerican |
1.911640E-01 |
| Caucasian-vs-Asian |
8.207200E-01 |
| AfricanAmerican-vs-Asian |
3.138800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.82420745176159E-12 |
| Male-vs-Female |
1.585500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.88455934086096E-12 |
| Normal-vs-Age(41-60Yrs) |
1.35447209004269E-14 |
| Normal-vs-Age(61-80Yrs) |
1.63768998362457E-12 |
| Normal-vs-Age(81-100Yrs) |
2.623700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.953600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.011500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.214800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.295400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.916000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.604200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.808300E-04 |
| Classical-VS-Follicular |
1.655400E-01 |
| Classical-VS-Other |
2.493400E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
3.825300E-04 |
| Tall-VS-Other |
8.567400E-01 |
| Tall-VS-Normal |
2.22044604925031E-16 |
| Follicular-VS-Other |
2.650400E-01 |
| Follicular-VS-Normal |
1.10750000004156E-06 |
| Other-VS-Normal |
5.72970000000117E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.2835739096131E-12 |
| Normal-vs-N1 |
1.4432899320127E-15 |
| N0-vs-N1 |
2.162100E-03 |
|
|
